Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity.
Animals
Antineoplastic Agents, Immunological
/ therapeutic use
Body Mass Index
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Heme Oxygenase-1
/ blood
Humans
Immunotherapy
Ipilimumab
/ therapeutic use
Kaplan-Meier Estimate
Linear Models
Lipoproteins, LDL
/ blood
Male
Melanoma
/ drug therapy
Mice
Mice, Inbred C57BL
Mice, Transgenic
Obesity
/ blood
Retrospective Studies
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
29
04
2020
revised:
07
10
2020
accepted:
03
12
2020
pubmed:
12
12
2020
medline:
15
12
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Antitumor immunity is impaired in obese mice. Mechanistic insight into this observation remains sparse and whether it is recapitulated in patients with cancer is unclear because clinical studies have produced conflicting and controversial findings. We addressed this by analyzing data from patients with a diverse array of cancer types. We found that survival after immunotherapy was not accurately predicted by body mass index or serum leptin concentrations. However, oxidized low-density lipoprotein (ox-LDL) in serum was identified as a suppressor of T-cell function and a driver of tumor cytoprotection mediated by heme oxygenase-1 (HO-1). Analysis of a human melanoma gene expression database showed a clear association between higher
Identifiants
pubmed: 33303575
pii: 2326-6066.CIR-20-0358
doi: 10.1158/2326-6066.CIR-20-0358
pmc: PMC7864876
mid: NIHMS1654273
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Ipilimumab
0
Lipoproteins, LDL
0
oxidized low density lipoprotein
0
Heme Oxygenase-1
EC 1.14.14.18
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
214-226Subventions
Organisme : BLRD VA
ID : I01 BX003714
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA238705
Pays : United States
Organisme : NIH HHS
ID : S10 OD025246
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
J Invest Dermatol. 2017 Aug;137(8):1792-1795
pubmed: 28442307
Nat Immunol. 2018 Dec;19(12):1330-1340
pubmed: 30420624
Annu Rev Pharmacol Toxicol. 2010;50:323-54
pubmed: 20055707
J Immunother Cancer. 2019 Aug 19;7(1):222
pubmed: 31426863
Cancer Immunol Immunother. 2019 Jul;68(7):1095-1106
pubmed: 31104075
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Eur J Cancer. 2013 Feb;49(3):642-57
pubmed: 23200191
J Immunol. 2018 Oct 1;201(7):1837-1841
pubmed: 30135180
Int J Obes (Lond). 2016 May;40(5):883-6
pubmed: 26841729
J Exp Med. 2010 May 10;207(5):1081-93
pubmed: 20439543
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Methods Mol Biol. 2010;610:403-17
pubmed: 20013192
Life Sci. 2018 Apr 1;198:79-86
pubmed: 29462603
Circulation. 2006 Nov 14;114(20):2178-89
pubmed: 17101869
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
World J Urol. 2019 Mar;37(3):507-514
pubmed: 29992381
Clin Exp Immunol. 2013 Apr;172(1):73-80
pubmed: 23480187
Cancer Res. 2016 Apr 15;76(8):2063-70
pubmed: 27197250
J Immunol. 2012 Aug 1;189(3):1311-21
pubmed: 22745381
Curr Opin Immunol. 2018 Apr;51:181-186
pubmed: 29655021
Trends Immunol. 2016 Jun;37(6):354-363
pubmed: 27105824
Trends Mol Med. 2016 Feb;22(2):88-98
pubmed: 26776093
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Cancer Cell. 2016 Jul 11;30(1):136-146
pubmed: 27411588
Sci Transl Med. 2018 Mar 14;10(432):
pubmed: 29540614
Contemp Oncol (Pozn). 2018 Mar;22(1A):23-32
pubmed: 29628790
Int J Obes (Lond). 2017 Aug;41(8):1162-1163
pubmed: 28584251
Cell Metab. 2019 Jul 2;30(1):143-156.e5
pubmed: 31031094
J Biol Chem. 2012 Sep 14;287(38):32113-23
pubmed: 22843690
Lipids. 2011 Dec;46(12):1169-79
pubmed: 21904795
Am J Pathol. 2006 Dec;169(6):2181-98
pubmed: 17148680
N Engl J Med. 2012 Nov 8;367(19):1792-802
pubmed: 23134381
Nat Immunol. 2012 Jul 19;13(8):707-12
pubmed: 22814340
Proc Natl Acad Sci U S A. 1987 May;84(9):2995-8
pubmed: 3472245
Nature. 2018 Jan 18;553(7688):347-350
pubmed: 29320474
J Clin Invest. 1997 Sep 1;100(5):1209-16
pubmed: 9276739
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Antioxid Redox Signal. 2011 Oct 15;15(8):2301-33
pubmed: 21338316
Cancer Immunol Res. 2021 Feb;9(2):227-238
pubmed: 33023966
Clin Cancer Res. 2005 May 15;11(10):3790-8
pubmed: 15897578
Nature. 2016 Mar 31;531(7596):651-5
pubmed: 26982734
J Biol Chem. 2007 Jul 13;282(28):20621-33
pubmed: 17430897
Cancer Res. 2009 Oct 15;69(20):8017-24
pubmed: 19808972
N Engl J Med. 1989 Apr 6;320(14):915-24
pubmed: 2648148
Mass Spectrom Rev. 2005 May-Jun;24(3):367-412
pubmed: 15389848
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
Sci Rep. 2017 Nov 7;7(1):14664
pubmed: 29116252
Immunity. 2019 Sep 17;51(3):548-560.e4
pubmed: 31471106
Nat Immunol. 2011 Mar;12(3):204-12
pubmed: 21321594
N Engl J Med. 1996 Feb 1;334(5):292-5
pubmed: 8532024
J Immunol. 2014 Jan 1;192(1):136-44
pubmed: 24273001
Clin Biochem. 2007 Oct;40(15):1129-34
pubmed: 17673194
Nature. 1998 Aug 27;394(6696):897-901
pubmed: 9732873